300318.SZ
Beijing Bohui Innovation Biotechnology Group Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 4.66
+0.65%Oct 12, 2026, 08:00 UTC
Bohui Innovation said it obtained a Class III medical-device registration certificate from China’s National Medical Products Administration for a chip-hybridization test kit detecting the Mycobacterium tuberculosis complex and mutations associated with rifampicin and isoniazid resistance.
Source:Oct 12, 2026, 07:57 UTC
China's National Medical Products Administration granted BGI Innovation a Class III medical-device registration certificate for a chip-hybridization test kit detecting Mycobacterium tuberculosis complex and rifampicin and isoniazid resistance mutations.
Source:Aug 25, 2026, 08:12 UTC
Bohui Innovation announced its first-half 2026 results, reporting a net loss of 15.6066 million yuan, an improvement from a loss of 18.6882 million yuan in the same period of 2025.
Source: